American Century Companies Inc. boosted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 10.8% during the 3rd quarter, HoldingsChannel reports. The fund owned 665,891 shares of the biopharmaceutical company’s stock after purchasing an additional 64,743 shares during the period. American Century Companies Inc.’s holdings in Amicus Therapeutics were worth $8,051,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Arbor Wealth Management LLC bought a new position in Amicus Therapeutics during the second quarter worth about $144,000. P.R. Herzig & Co. Inc. bought a new position in Amicus Therapeutics during the second quarter worth about $156,000. Quantitative Systematic Strategies LLC bought a new position in Amicus Therapeutics during the second quarter worth about $179,000. TCW Group Inc. bought a new position in Amicus Therapeutics during the second quarter worth about $245,000. Finally, Strs Ohio lifted its holdings in Amicus Therapeutics by 32.2% during the second quarter. Strs Ohio now owns 16,000 shares of the biopharmaceutical company’s stock worth $249,000 after acquiring an additional 3,900 shares in the last quarter.

FOLD opened at $10.40 on Thursday. Amicus Therapeutics, Inc. has a 1 year low of $9.84 and a 1 year high of $17.62. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of -3.56 and a beta of 1.48. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.03 and a current ratio of 9.12.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.04). Amicus Therapeutics had a negative net margin of 463.82% and a negative return on equity of 52.03%. The firm had revenue of $20.60 million during the quarter, compared to analyst estimates of $23.56 million. During the same period in the prior year, the business earned ($0.41) EPS. The business’s revenue for the quarter was up 89.0% compared to the same quarter last year. On average, analysts expect that Amicus Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.

Several research analysts have weighed in on the company. BidaskClub upgraded Amicus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Tuesday, November 6th. Citigroup began coverage on Amicus Therapeutics in a report on Monday, October 29th. They set a “neutral” rating and a $12.00 target price on the stock. Cowen reissued a “buy” rating and issued a $31.00 price target on shares of Amicus Therapeutics in a research note on Friday, October 12th. Chardan Capital reissued a “hold” rating and issued a $15.00 price target on shares of Amicus Therapeutics in a research note on Friday, October 12th. Finally, Zacks Investment Research raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research note on Monday, October 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $19.50.

In other news, major shareholder Life Sciences Maste Perceptive purchased 50,000 shares of the company’s stock in a transaction on Friday, September 21st. The shares were purchased at an average price of $12.53 per share, with a total value of $626,500.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO William D. Baird III sold 10,000 shares of Amicus Therapeutics stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $12.23, for a total value of $122,300.00. Following the completion of the sale, the chief financial officer now directly owns 127,622 shares in the company, valued at approximately $1,560,817.06. The disclosure for this sale can be found here. Insiders acquired a total of 620,000 shares of company stock worth $7,505,000 in the last three months. Company insiders own 2.90% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Amicus Therapeutics, Inc. (FOLD) Holdings Lifted by American Century Companies Inc.” was first published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2018/11/22/amicus-therapeutics-inc-fold-holdings-lifted-by-american-century-companies-inc.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Further Reading: What are trading strategies for the 52-week high/low?

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.